Tango Therapeutics, Inc.

Tango Therapeutics, Inc.verified

TNGX

Price:

$8.28

Market Cap:

$887.15M

Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company also develops Ubiquitin-specific protease 1, an inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. Tango Therapeutics, Inc. has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. The company was founded in...[Read more]

Industry

Biotechnology

IPO Date

2020-09-03

Stock Exchange

NASDAQ

Ticker

TNGX

The ROE as of September 2024 (TTM) for Tango Therapeutics, Inc. (TNGX) is -44.73%

According to Tango Therapeutics, Inc.’s latest financial reports and current stock price. The company's current ROE is -44.73%. This represents a change of 298.83% compared to the average of -11.21% of the last 4 quarters.

Tango Therapeutics, Inc. (TNGX) Historical ROE (quarterly & annually)

How has TNGX ROE performed in the past?

The mean historical ROE of Tango Therapeutics, Inc. over the last ten years is -82.62%. The current -44.73% ROE has changed -45.87% with respect to the historical average. Over the past ten years (40 quarters), TNGX's ROE was at its highest in in the June 2021 quarter at -2.78%. The ROE was at its lowest in in the June 2020 quarter at -34213.96%.

Quarterly (TTM)
Annual

Average

-82.62%

Median

-43.36%

Minimum

-178.30%

Maximum

-16.89%

Tango Therapeutics, Inc. (TNGX) ROE by Quarter and Year

Discovering the peaks and valleys of Tango Therapeutics, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 156.70%

Maximum Annual ROE = -16.89%

Minimum Annual Increase = -87.43%

Minimum Annual ROE = -178.30%

Quarterly (TTM)
Annual
YearROEChange
2023-40.20%-7.30%
2022-43.36%156.70%
2021-16.89%-87.43%
2020-134.36%-24.64%

Tango Therapeutics, Inc. (TNGX) Average ROE

How has TNGX ROE performed in the past?

The current ROE of Tango Therapeutics, Inc. (TNGX) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

3-year avg

-33.48%

5-year avg

-82.62%

10-year avg

-82.62%

Tango Therapeutics, Inc. (TNGX) ROE vs. Peers

How is TNGX’s ROE compared to its peers?

Tango Therapeutics, Inc.’s ROE is greater than Third Harmonic Bio, Inc. (-6.80%), greater than Cullinan Oncology, Inc. (-28.37%), greater than Edgewise Therapeutics, Inc. (-28.01%), greater than Rallybio Corporation (-74.08%), greater than Monte Rosa Therapeutics, Inc. (-70.40%), greater than Connect Biopharma Holdings Limited (-3.40%), greater than Tyra Biosciences, Inc. (-27.13%), greater than RAPT Therapeutics, Inc. (-86.04%), greater than Xilio Therapeutics, Inc. (-176.51%), greater than Mineralys Therapeutics, Inc. (-42.61%), less than Foghorn Therapeutics Inc. (140.34%), greater than Shattuck Labs, Inc. (-68.65%), greater than Kymera Therapeutics, Inc. (-28.88%), greater than Nurix Therapeutics, Inc. (-67.78%), greater than TCR2 Therapeutics Inc. (-89.51%), greater than Revolution Medicines, Inc. (-34.57%), greater than Black Diamond Therapeutics, Inc. (-69.08%), greater than Atreca, Inc. (-195.22%), greater than Passage Bio, Inc. (-70.73%), greater than Relay Therapeutics, Inc. (-43.66%), greater than Stoke Therapeutics, Inc. (-57.89%), greater than Pliant Therapeutics, Inc. (-41.05%), greater than Arvinas, Inc. (-55.59%),

Build a custom stock screener for Tango Therapeutics, Inc. (TNGX) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Tango Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Tango Therapeutics, Inc. (TNGX) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Tango Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the ROE?

How can you use the ROE?

What is Tango Therapeutics, Inc.'s ROE?

How is the ROE calculated for Tango Therapeutics, Inc. (TNGX)?

What is the highest ROE for Tango Therapeutics, Inc. (TNGX)?

What is the 3-year average ROE for Tango Therapeutics, Inc. (TNGX)?

What is the 5-year average ROE for Tango Therapeutics, Inc. (TNGX)?

How does the current ROE for Tango Therapeutics, Inc. (TNGX) compare to its historical average?